Previous 10 | Next 10 |
Worldwide revenue of $56.6 million – an increase of 13.4% year over year U.S. revenue of $46.1 million – an increase of 16.0% year over year International revenue of $10.5 million – an increase of 3.1% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a l...
AAPL , ACA , ACAD , ADTN , AGI , AGNC , AKS , ALEX , ALSN , APA , ARES , ATRC , AWK , AXTI , AZPN , BFAM , BLDP , BOOT , CACI , CATM , CERS , CF , CHDN , CHEF , CLI , CLR , CMPR , CNMD , CNXN , COLM , CONE , CREE , CRUS , CRY , CSGS , CTSH , CW , DDD , ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019. AtriCure will host a conference cal...
Thinly traded AtriCure ( ATRC +6.8% ) is up on average volume, a modest 200K shares, as JPMorgan steps in to defend the stock after yesterday's 10% selloff in apparent reaction to a bearish report from Culper Research . More news on: AtriCure, Inc., Healthcare stocks news, S...
Clinical evidence demonstrates that AtriClip ® devices exclude and electrically isolate the left atrial appendage AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Morgan Stanley 17 th Annual Global Healthcare Conference in New York C...
Now China claims US broke the negotiation agreement The market futures plunge after China threatens retaliation. Then China backtracks, and the market goes back up. China claims the US broke the agreement; we say China did. Am I the only one who is bored with the whole nonsense? All I can ...
Quick Take AtriCure ( ATRC ) announced it has agreed to acquire SentreHEART for $40 million plus additional contingent consideration of up to $260 million. SentreHEART is developing percutaneous left atrial appendage management solutions. With the deal, ATRC is gaining promising techno...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc., a privately held developer of percutaneous left atrial a...
News, Short Squeeze, Breakout and More Instantly...
2024-07-31 08:00:12 ET Rick Wise from Stifel Nicolaus issued a price target of $26.00 for ATRC on 2024-07-31 06:57:00. The adjusted price target was set to $26.00. At the time of the announcement, ATRC was trading at $22. The overall price target consensus is at $56.00 w...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...